Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can five radiation doses match longer treatment for breast cancer?

NCT ID NCT05776147

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This study looks back at the records of 461 women in Brazil who received a short, high-dose radiation schedule after breast cancer surgery. The schedule, called extreme hypofractionation, delivers 5 doses of 5.2 Gy instead of many smaller doses. Researchers want to see how well this approach controls cancer in the breast area and what side effects it causes. The goal is to understand whether this shorter treatment works as well as longer courses in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extreme hypofractionated radiotherapy (5 fractions of 5.2 Gy)
What this could lead to
If the results are positive, this could support the wider use of a shorter, more convenient radiotherapy schedule for breast cancer patients.
What could go wrong
Because this is a retrospective review of existing records, it cannot prove cause and effect, and the findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

461 people

The number who actually took part.

Started

Nov 2023

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with breast cancer undergoing radiotherapy with extreme hypofractionation.

Ages

18 years and older

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women over 18 years old; * Diagnosis of breast cancer of any molecular subtype; * Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively; * Treated from December/2019 onward; * With clinical and treatment data available in medical records. Exclusion Criteria: * The protocol does not provide exclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Radiotherapy side effect

Contacts and locations

Locations

  • A.C. Camargo Cancer Center

    São Paulo, São Paulo, 01.509-001, Brazil

  • BP - A Beneficência Portuguesa de São Paulo

    São Paulo, São Paulo, 01.323-030, Brazil

  • HAOC - Hospital Alemão Oswaldo Cruz

    São Paulo, São Paulo, 01.323-020, Brazil

  • Hospital Márcio Cunha da Fundação São Francisco Xavier (HMC-FSFX)

    Ipatinga, Minas Gerais, 35.160-158, Brazil

  • Hospital Sírio-Libanês DF

    Brasília, Federal District, 70.200-730, Brazil

  • Hospital Sírio-Libanês SP

    São Paulo, São Paulo, 01.308-050, Brazil

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP

    Ribeirão Preto, São Paulo, 14.015-010, Brazil

  • ICC - Instituto do Câncer do Ceará

    Fortaleza, Ceará, 60.430-230, Brazil

  • Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ)

    Rio de Janeiro, Rio de Janeiro, 22.793-080, Brazil

  • Oncominas - Clínica de Oncologia no Sul de Minas

    Pouso Alegre, Minas Gerais, 37.554-216, Brazil

  • Real Hospital Português de Beneficência em Pernambuco

    Recife, Pernambuco, 50.030-230, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.